137 related articles for article (PubMed ID: 8195035)
21. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.
Bailey SM; Wyatt MD; Friedlos F; Hartley JA; Knox RJ; Lewis AD; Workman P
Br J Cancer; 1997; 76(12):1596-603. PubMed ID: 9413948
[TBL] [Abstract][Full Text] [Related]
22. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
23. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
Doherty GP; Leith MK; Wang X; Curphey TJ; Begleiter A
Br J Cancer; 1998 Apr; 77(8):1241-52. PubMed ID: 9579829
[TBL] [Abstract][Full Text] [Related]
24. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
Lartigau E; Guichard M
Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
[TBL] [Abstract][Full Text] [Related]
25. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
Sharp SY; Kelland LR; Valenti MR; Brunton LA; Hobbs S; Workman P
Mol Pharmacol; 2000 Nov; 58(5):1146-55. PubMed ID: 11040064
[TBL] [Abstract][Full Text] [Related]
26. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
27. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
28. Role of redox cycling and activation by DT-diaphorase in the cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs.
Miŝkiniene V; Sergediene E; Nemeikaite A; Segura-Aguilar J; Cenas N
Cancer Lett; 1999 Nov; 146(2):217-22. PubMed ID: 10656629
[TBL] [Abstract][Full Text] [Related]
29. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
[TBL] [Abstract][Full Text] [Related]
30. Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.
Bailey SM; Suggett N; Walton MI; Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):649-53. PubMed ID: 1544832
[TBL] [Abstract][Full Text] [Related]
31. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
Lambin P; Guichard M; Chavaudra N; Malaise EP
Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing the induction of DT-diaphorase activity by 1,2-dithiole-3-thione in human tumor cell lines.
Begleiterabc A; Leith MK; Doherty GP; Digbya TJ; Pan S
Biochem Pharmacol; 2001 Apr; 61(8):955-64. PubMed ID: 11286987
[TBL] [Abstract][Full Text] [Related]
33. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
34. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
36. Dual action of tirapazamine in the induction of DNA strand breaks.
Jones GD; Weinfeld M
Cancer Res; 1996 Apr; 56(7):1584-90. PubMed ID: 8603406
[TBL] [Abstract][Full Text] [Related]
37. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
38. Pre- and post-irradiation radiosensitization by SR 4233.
Zeman EM; Brown JM
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
[TBL] [Abstract][Full Text] [Related]
39. Influence of DT diaphorase on quinone-mediated genotoxicity in human and fish cell lines.
Hasspieler BM; Haffner GD; Adeli K
Mutat Res; 1996 May; 360(1):43-9. PubMed ID: 8657209
[TBL] [Abstract][Full Text] [Related]
40. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
Keohane A; Godden J; Stratford IJ; Adams GE
Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
